Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis

Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis

BackgroundDespite durable responses achieved with Immune Checkpoint Inhibitors (ICIs), data about optimal duration of treatment, especially in the context of adverse events, remain scarce.ObjectiveTo systematically review the evidence concerning the impact of treatment discontinuation with ICIs for...

Full description

Saved in:
Bibliographic Details
Main Authors: Konstantinos Lallas, Eftychia Chatziioannou, Derya Durak, Georg Frey, Lina Maria Serna-Higuita, Marie-Lena Rasch, Athanassios Kyrgidis, Eleni Timotheadou, Zoe Apalla, Ulrike Leiter, Lukas Flatz, Aimilios Lallas, Teresa Amaral
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
immune checkpoint inhibitors
therapy discontinuation
stage IV
overall survival
melanoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1524945/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items